FGEN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.67M

-96.69%

-3.885

+94.25%

0.00

-100%

-4.290

-443.2%

0.00

-100%

-4.250

+126.06%

Estimates Revision

The market is revising Downward the revenue expectations for FibroGen, Inc. (FGEN) for FY2025, with the revenue forecasts being adjusted by -2.17% over the past three months. During the same period, the stock price has changed by -11.41%.

Revenue Estimates for FY2025

Revise Downward

-2.17%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+10.43%

In Past 3 Month

Stock Price

Go Down

-11.41%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast FGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FGEN is 43.00 USD with a low forecast of 43.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

43.00

Averages

43.00

High

43.00

Current: 0.000

Low

43.00

Averages

43.00

High

43.00

H.C. Wainwright

NULL -> Buy

upgrade

$10 -> $43

2025-08-07

Reason

H.C. Wainwright

Price Target

$10 -> $43

2025-08-07

upgrade

NULL -> Buy

Reason

H.C. Wainwright adjusted the firm's price target on FibroGen to $43 from $10 and keeps a Buy rating on the shares following the recent reverse stock split. The firm also cites an increased discount rate pending visibility from both the FG-3246 and roxadustat programs after Fibrogen disclosed "positive details" from a Type C meeting with the FDA. The firm, which calls the update an "important step forward for Fibrogen and roxa," awaits additional updates, including trial start dates and possible inclusion of a development/commercial partner.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$10

2025-03-18

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$10

2025-03-18

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$10

2025-02-20

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$10

2025-02-20

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for FibroGen Inc (FGEN.O) is -0.54, compared to its 5-year average forward P/E of -4.68. For a more detailed relative valuation and DCF analysis to assess FibroGen Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.68

Current PE

-0.54

Overvalued PE

1.03

Undervalued PE

-10.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.64

Current EV/EBITDA

0.58

Overvalued EV/EBITDA

0.16

Undervalued EV/EBITDA

-7.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.39

Current PS

5.92

Overvalued PS

9.99

Undervalued PS

0.78

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

FGEN News & Events

Events Timeline

No data

News

9.0

2025-12-15Globenewswire

FibroGen Receives FDA Orphan Drug Designation for Roxadustat in MDS Treatment

9.0

2025-12-15Newsfilter

FibroGen Receives FDA Orphan Drug Designation for Roxadustat, Plans Phase 3 Submission in Q4 2025

9.0

2025-12-15NASDAQ.COM

FibroGen: Roxadustat Receives Orphan Drug Designation from FDA for MDS

People Also Watch

Frequently Asked Questions

What is FibroGen Inc (FGEN) stock price today?

The current price of FGEN is 9.71 USD — it has increased 7.11 % in the last trading day.

What is FibroGen Inc (FGEN)'s business?

Kyntra Bio, Inc., formerly FibroGen, Inc., is a biopharmaceutical company. The Company is focused on development of novel therapies in oncology and rare disease. The Company continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.

What is the price predicton of FGEN Stock?

What is FibroGen Inc (FGEN)'s revenue for the last quarter?

FibroGen Inc revenue for the last quarter amounts to 1.08M USD, increased 774.80 % YoY.

What is FibroGen Inc (FGEN)'s earnings per share (EPS) for the last quarter?

FibroGen Inc. EPS for the last quarter amounts to 49.61 USD, decreased -1267.29 % YoY.

What changes have occurred in the market's expectations for FibroGen Inc (FGEN)'s fundamentals?

How many employees does FibroGen Inc (FGEN). have?

FibroGen Inc (FGEN) has 225 emplpoyees as of January 09 2026.

What is FibroGen Inc (FGEN) market cap?

Today FGEN has the market capitalization of 102.46M USD.